Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio is a promising biopharmaceutical company with a unique approach to genetic medicines using RNA editing technology. Their focus on stabilizing glutamine synthetase (GS) has solid human genetic evidence to support its effectiveness in reducing ammonia levels, which is a shared driver of disease in UCD and HE patients. With a strong preclinical data package, multiple established regulatory paths, and a risk-mitigated pipeline, Korro Bio has the potential to achieve meaningful benefits and become a leader in the field. Despite being a development stage company, we estimate a 20% probability of approval and $2B peak sales for KRRO-121, supporting a 12-month price target of $20 per share. However, we acknowledge the need for additional funding in the future, which may involve dilution or restrictive covenants.

Bears say

Korro Bio is a clinical-stage biopharmaceutical company with a focus on developing genetic medicines through RNA editing technology. While the company has intriguing prospects in the rare disease market with its experimental medication, KRRO-121, there are significant investment concerns. The company has not yet proved its ability to successfully develop and commercialize a product, and faces fierce competition in the biotechnology and pharmaceutical industries. Additionally, the company's genetic editing approach may face challenges from regulators and patent infringement suits, which could lead to significant legal expenses. Overall, there are numerous risks that could impact the success and profitability of Korro Bio, which warrants a negative outlook from a financial analyst.

KRRO has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 9 analysts, KRRO has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.